Key result
Regadenoson during myocardial perfusion imaging can trigger seizures and epileptogenic activity in susceptible patients.
Why the study?
Epileptogenic activity is an uncommon yet potentially severe adverse effect of regadenoson used in cardiac stress testing, requiring increased awareness and screening.
Does regadenoson use during myocardial perfusion imaging increase the risk of seizures in susceptible individuals?
Does regadenoson use during myocardial perfusion imaging increase the risk of seizures in susceptible individuals?
Highlights the uncommon but severe risk of seizures associated with regadenoson during myocardial perfusion imaging, emphasizing the need for careful screening of susceptible patients.
Answers are grounded in this paper and cite their sources.
May warrant seizure screening before regadenoson MPI; leaves open incidence and mitigation strategies.
Regadenoson is a selective adenosine 2a (A2a) receptor agonist that is used in cardiac stress testing to evaluate for ischemic heart disease and has largely replaced adenosine in the modern era. Since adenosine receptors are involved in synaptic transmission between neurons throughout the central nervous system (CNS) including the cerebral cortex, hippocampus, and other structures as well, regadenoson can lower the seizure threshold in susceptible individuals. Epileptogenic activity is an uncommon yet potentially severe adverse effect of regadenoson use, and therefore, more awareness is required in screening patients at risk and evaluating alternate ways to investigate coronary artery disease (CAD) in susceptible individuals.
No takes yet. Share an insight, caveat, or question.
Radwan et al. (2019) conducted a review in Ischemic heart disease. Regadenoson was evaluated on Seizure / epileptogenic activity. Regadenoson use during myocardial perfusion imaging can lower the seizure threshold and cause epileptogenic activity in susceptible individuals.
Synapse has enriched 10 related papers. Consider them for comparative context: